Flag of the European Union EU Clinical Trials Register Help

Clinical trials for II

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11,931 result(s) found for: II. Displaying page 597 of 597.
    «« First « Previous 589  590  591  592  593  594  595  596  597 
    EudraCT Number: 2010-022638-96 Sponsor Protocol Number: CAFQ056B2214 Start Date*: 2011-06-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of AFQ056 in adolescent patients with Fragile X Syndrome
    Medical condition: Fragile X Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) FR (Completed) DK (Completed) DE (Completed) ES (Completed) Outside EU/EEA IT (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000936-23 Sponsor Protocol Number: C20-15 Start Date*: 2020-03-09
    Sponsor Name:INSERM
    Full Title: Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults
    Medical condition: COVID-19 - Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen < 72 hours prior to randomization. - Illness of any durat...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) AT (Completed) PT (Completed) SK (Completed) CZ (Completed) NO (Prematurely Ended) IE (Prematurely Ended) HU (Completed) ES (Ongoing) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003539-12 Sponsor Protocol Number: EFC16216 Start Date*: 2017-11-15
    Sponsor Name:Bioverativ USA Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WITHOUT A RECENT HISTORY OF BLOOD TRANSFU...
    Medical condition: Primary Cold Agglutinin Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10073785 Autoimmune haemolytic anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) NO (Completed) ES (Ongoing) BE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002443-28 Sponsor Protocol Number: ACE-CL-311/D8221C00001 Start Date*: 2019-05-08
    Sponsor Name:Acerta Pharma B.V.
    Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investiga...
    Medical condition: Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) HU (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004362-34 Sponsor Protocol Number: CA209-8TT Start Date*: 2020-03-24
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
    Medical condition: pan tumor
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) NO (Completed) PL (Trial now transitioned) GR (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Completed) PT (Completed) CZ (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004225-24 Sponsor Protocol Number: CNTO1275CRD3004 Start Date*: 2021-03-17
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance i...
    Medical condition: Moderately to Severely Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2019-001862-13 Sponsor Protocol Number: AB19001 Start Date*: 2020-03-12
    Sponsor Name:ABScience
    Full Title: A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo ...
    Medical condition: patients suffering from Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) FR (Trial now transitioned) BE (Prematurely Ended) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) PT (Ongoing) ES (Restarted) DK (Trial now transitioned) PL (Ongoing) IE (Prematurely Ended) IT (Prematurely Ended) NO (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004891-36 Sponsor Protocol Number: NN7415-4307 Start Date*: 2019-11-20
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B without inhibitors
    Medical condition: Haemophilia A Haemophilia B
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10018938 Haemophilia A (Factor VIII) LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DK (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) SK (Prematurely Ended) DE (Trial now transitioned) BG (Completed) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) PT (Trial now transitioned) HR (Completed) HU (Trial now transitioned) LT (Trial now transitioned) EE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002391-39 Sponsor Protocol Number: CLI-05993AB1-06 Start Date*: 2021-11-02
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 26 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 μg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF B...
    Medical condition: ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2- AGONISTS
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004855 10003555 Asthma bronchial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) SK (Completed) CZ (Completed) BG (Completed) PL (Completed) IT (Completed) LV (Completed) ES (Ongoing) FI (Completed) GR (Completed) NL (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001594-24 Sponsor Protocol Number: CABL001E2201 Start Date*: 2018-10-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treat...
    Medical condition: Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PL (Completed) DK (Completed) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003660-31 Sponsor Protocol Number: B7841005 Start Date*: 2020-09-07
    Sponsor Name:Pfizer Inc.
    Full Title: An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A or B Patients With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis
    Medical condition: Hemophilia A or B
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060613 Hemophilia A (Factor VIII) LLT
    20.0 100000004850 10060612 Hemophilia A LLT
    20.0 100000004850 10060614 Hemophilia B (Factor IX) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) FR (Completed) BG (Completed) GB (GB - no longer in EU/EEA) ES (Restarted) IE (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 589  590  591  592  593  594  595  596  597 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 07:24:14 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA